From GlobeNewswire: 2024-04-06 16:16:00

The V-INITIATE trial results show that early initiation of Leqvio led to significant LDL-C reduction for ASCVD patients who could not reach their goal on statin therapy alone. A greater proportion of patients on Leqvio achieved guideline-recommended LDL-C levels compared to usual care, highlighting the need for more aggressive LDL-C lowering. The safety profile of Leqvio was consistent with previous studies. Data presented at the ACC’s Annual Scientific Session & Expo demonstrate the benefits of adding Leqvio to statin therapy early on in ASCVD treatment to better manage LDL-C levels and improve outcomes for patients.



Read more at GlobeNewswire: New Novartis data show early addition of twice-yearly*